Aytu BioPharma Inc. reported fiscal 2026 second‑quarter results for the period ended December 31 2025, posting net revenue of $15.2 million and an adjusted EBITDA of $(0.8) million. The company recorded a net loss of $10.6 million, driven largely by an $8.2 million derivative warrant liability and a $7.2 million launch‑investment expense for its new major‑depressive‑disorder drug, EXXUA. Earnings per share fell to $‑1.05, a miss of $0.79 versus the consensus estimate of $‑0.26. Cash and cash equivalents stood at $30.0 million at year‑end, down from $31.0 million at June 30 2025.
The $15.2 million in revenue represented a 6% year‑over‑year decline from $16.2 million in the same quarter of 2025. The decline was largely driven by a $0.5 million drop in the company’s legacy ADHD portfolio, which generated $13.2 million versus $13.8 million previously, and a $0.7 million decline in the pediatric portfolio, which fell to $1.7 million from $2.4 million. EXXUA contributed $0.2 million in initial stocking revenue, and the company’s RxConnect platform is beginning to generate early prescriber uptake across 27 states.
Gross margin contracted to 63.5% from 66.5% year‑ago, reflecting the impact of launch‑related costs and a $1.1 million inventory write‑down. The net loss was amplified by the $8.2 million derivative warrant liability, a non‑cash charge that increased as the company’s share price rose. Management noted that the launch‑investment expense—now capped at under $8 million—was a one‑time cost that will be amortized over the next few quarters as EXXUA scales.
CEO Josh Disbrow said the quarter was “a truly momentous time” and an “inflection point” for Aytu, emphasizing the differentiated mechanism of action of EXXUA and the company’s confidence that early market traction will accelerate. CFO Ryan Selhorn highlighted that the company’s gross margin decline was “primarily due to transition‑related expenses and an inventory write‑down” and that the $8 million launch‑investment budget was a strategic investment that will pay off as the product gains market share.
The market reaction was muted, with analysts noting that the EPS miss outweighed the revenue beat. The company’s guidance for the next quarter was not updated, but management expressed confidence that the launch of EXXUA will drive future revenue growth and that cost controls will help restore profitability as the product scales.
Aytu’s results underscore the trade‑off between short‑term losses and long‑term growth. While the company’s legacy portfolios continue to generate steady revenue, the heavy investment in EXXUA’s launch and the associated non‑cash charges have widened the net loss and compressed margins. The company’s focus on RxConnect and early prescriber uptake suggests a strategic pivot toward high‑margin specialty products, but the path to profitability will depend on scaling EXXUA, managing launch costs, and mitigating the impact of derivative warrant liabilities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.